These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17683063)

  • 1. Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer.
    Venkataraman G; Heinze G; Holmes EW; Ananthanarayanan V; Bostwick DG; Paner GP; Bradford-De La garza CM; Brown HG; Flanigan RC; Wojcik EM
    Prostate; 2007 Oct; 67(14):1524-36. PubMed ID: 17683063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.
    Sengupta S; Cheville JC; Lohse CM; Zincke H; Myers RP; Riehle DL; Pankratz VS; Blute ML; Sebo TJ
    Urology; 2006 Jul; 68(1):94-8. PubMed ID: 16844452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors.
    Bantis A; Gonidi M; Athanassiades P; Tsolos Ch; Liossi A; Aggelonidou E; Athanassiadou AM; Petrakakou E; Athanassiadou P
    J Exp Clin Cancer Res; 2005 Jun; 24(2):273-8. PubMed ID: 16110761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    Abaza R; Diaz LK; Laskin WB; Pins MR
    J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer.
    Häggarth L; Auer G; Busch C; Norberg M; Häggman M; Egevad L
    Scand J Urol Nephrol; 2005; 39(5):387-92. PubMed ID: 16257840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neurocomputational model for prostate carcinoma detection.
    Kalra P; Togami J; Bansal B S G; Partin AW; Brawer MK; Babaian RJ; Ross LS; Niederberger CS
    Cancer; 2003 Nov; 98(9):1849-54. PubMed ID: 14584066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
    Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
    Choo R; Danjoux C; Morton G; Szumacher E; Sugar L; Gardner S; Kim M; Choo CM; Klotz L
    Prostate; 2007 Nov; 67(15):1614-20. PubMed ID: 17823923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network.
    Chun FK; Graefen M; Briganti A; Gallina A; Hopp J; Kattan MW; Huland H; Karakiewicz PI
    Eur Urol; 2007 May; 51(5):1236-40; discussion 1241-3. PubMed ID: 16945477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
    Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA
    Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Flow cytometry in prostate cancer. Evaluation of its feasibility for biopsy specimens and correlation with grading].
    Ferrara G; Monaco R; Capasso A; Bellomo PF; Fruttero A; Pugno F; Nappi O; Ruà S
    Pathologica; 1998 Feb; 90(1):14-9. PubMed ID: 9628974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
    Guzzo TJ; Levin BM; Lee R; Guo M; Chen Z; Whittington R; Tomaszewski J; Malkowicz SB
    Urology; 2008 Apr; 71(4):723-7. PubMed ID: 18387401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does any correlation exist between the Gleason classification system and the computer-assisted microscope analysis of Feulgen-stained nuclei features in human prostate adenocarcinoma?
    Petein M; Decaestecker C; Segers V; Janssen T; Fourmarier M; Van Leer P; van Velthoven R; Schulman C; Pasteels JL; Kiss R
    Anal Cell Pathol; 1996 Dec; 12(3):159-71. PubMed ID: 9025992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?
    Stav K; Judith S; Merald H; Leibovici D; Lindner A; Zisman A
    Urol Oncol; 2007; 25(5):383-6. PubMed ID: 17826654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.